Celery seed derived reconstituted lipid nanoparticles as an innate neuron-targeted neuroprotective nanomedicine for ischemic stroke treatment.

IF 10.6 1区生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Journal of Nanobiotechnology Pub Date : 2025-04-17 DOI:10.1186/s12951-025-03372-4

Dan Han, Jiaxing Zhang, Dingran Li, Cheng Wang

{"title":"Celery seed derived reconstituted lipid nanoparticles as an innate neuron-targeted neuroprotective nanomedicine for ischemic stroke treatment.","authors":"Dan Han, Jiaxing Zhang, Dingran Li, Cheng Wang","doi":"10.1186/s12951-025-03372-4","DOIUrl":null,"url":null,"abstract":"Background: Ischemic stroke (IS) is the leading cause of worldwide death while the discovery and effective delivery of neuroprotective agents for satisfied IS treatment is still challenging.Results: In this study, we discover that celery seed (CS) derived reconstituted lipid nanoparticles (CS-rLNPs) can effectively penetrate across blood-brain barrier (BBB) with increased distribution to the brain. Especially, CS-rLNPs show innate neuron-targeting ability to primarily bind to neuron in the cerebral ischemic area, which is not reported by any parallel studies. Moreover, CS-rLNPs are found to exert therapeutic effects on IS, which effectively restore the function of model mice. Further studies reveal that the therapeutic effects are realized through TLR4/MyD88/NF-κB p65 pathway regulated anti-inflammation and anti-apoptosis mechanisms.Conclusions: Therefore, CS-rLNPs can serve as a neuron-targeted neuroprotective nanomedicine for IS treatment.","PeriodicalId":16383,"journal":{"name":"Journal of Nanobiotechnology","volume":"23 1","pages":"298"},"PeriodicalIF":10.6000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004799/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nanobiotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1186/s12951-025-03372-4","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Ischemic stroke (IS) is the leading cause of worldwide death while the discovery and effective delivery of neuroprotective agents for satisfied IS treatment is still challenging.

Results: In this study, we discover that celery seed (CS) derived reconstituted lipid nanoparticles (CS-rLNPs) can effectively penetrate across blood-brain barrier (BBB) with increased distribution to the brain. Especially, CS-rLNPs show innate neuron-targeting ability to primarily bind to neuron in the cerebral ischemic area, which is not reported by any parallel studies. Moreover, CS-rLNPs are found to exert therapeutic effects on IS, which effectively restore the function of model mice. Further studies reveal that the therapeutic effects are realized through TLR4/MyD88/NF-κB p65 pathway regulated anti-inflammation and anti-apoptosis mechanisms.

Conclusions: Therefore, CS-rLNPs can serve as a neuron-targeted neuroprotective nanomedicine for IS treatment.

查看原文本刊更多论文

芹菜籽衍生的重组脂质纳米颗粒作为先天性神经元靶向治疗缺血性卒中的神经保护纳米药物。

背景：缺血性脑卒中（IS）是世界范围内死亡的主要原因，而神经保护剂的发现和有效递送仍然具有挑战性。结果：在本研究中，我们发现芹菜籽（CS）衍生的重组脂质纳米颗粒（CS- rlnps）可以有效地穿透血脑屏障（BBB），并增加分布到大脑。特别是CS-rLNPs表现出先天的神经元靶向能力，主要结合脑缺血区域的神经元，这一点尚无相关研究报道。此外，CS-rLNPs对IS有治疗作用，能有效恢复模型小鼠的功能。进一步研究表明，其治疗作用是通过TLR4/MyD88/NF-κB p65通路调控抗炎症和抗凋亡机制实现的。结论：CS-rLNPs可作为神经元靶向的神经保护纳米药物治疗IS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Nanobiotechnology BIOTECHNOLOGY & APPLIED MICROBIOLOGY-NANOSCIENCE & NANOTECHNOLOGY

CiteScore

13.90

自引率

4.90%

发文量

493

审稿时长

16 weeks

期刊介绍： Journal of Nanobiotechnology is an open access peer-reviewed journal communicating scientific and technological advances in the fields of medicine and biology, with an emphasis in their interface with nanoscale sciences. The journal provides biomedical scientists and the international biotechnology business community with the latest developments in the growing field of Nanobiotechnology.